In adults with type 2 diabetes, more participants reached the metabolic composite endpoint with pooled semaglutide doses than with comparators (29.1% vs 11.4%).
In plain wordsIn adults with type 2 diabetes, more people reached the combined HbA1c, blood pressure and cholesterol goal on semaglutide than on comparators.
- Peptide
- Semaglutide
- Outcome
- IncreaseMetabolic composite endpoint, semaglutide doses pooled
- Study
n = 7,633
- Comparator
- Comparators (pooled)
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- 0.5 or 1.0 mg once weekly · subcutaneousAs given in this study (human).
Measurements
- Composite endpoint proportion
- 29.1%
- semaglutide pooled
- Composite endpoint proportion
- 11.4%
- comparators
Source sentences
Likewise, when the OW SC semaglutide doses were pooled, significantly higher proportions of patients receiving semaglutide achieved the composite metabolic endpoint versus comparators (29.1% vs. 11.4%, respectively; p < .0001).
2 context sentences(design, population, supporting numbers)
Using patient-level data pooled by treatment, proportions of participants achieving the metabolic composite endpoint, defined as glycated haemoglobin <7% (<53 mmol/mol), blood pressure <140/90 mmHg and non-high-density lipoprotein cholesterol <130 mg/dl (<3.37 mmol/L), were evaluated following baseline adjustments.
Participants with T2D (aged ≥18 years) and glycated haemoglobin ≥7.0% (≥53 mmol/mol) who had been randomized to OW SC semaglutide (0.5 or 1.0 mg) or comparator in addition to background medication.